Home › IVA
Inventiva S A (IVA) Financials Data
Debt to Equity Ratio
About Inventiva S A
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Real-Time Dow Stock List Congresswoman Nancy Pelosi Stock Tracker Top 100 popular stocks on Robinhood
Cap: | Volume (24h):